Pharma Mar, S.A.'s latest marketcap:
As of 11/06/2025, Pharma Mar, S.A.'s market capitalization has reached $1.41 B. According to our data, Pharma Mar, S.A. is the 8292th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 1.41 B |
| Revenue (ttm) | 206.87 M |
| Net Income (ttm) | 39.24 M |
| Shares Out | 17.21 M |
| EPS (ttm) | 2.25 |
| Forward PE | 17.91 |
| Ex-Dividend Date | 06/25/2025 |
| Earnings Date | 10/30/2025 |
Pharma Mar, S.A.'s yearly market capitalization.
| Date | Market Cap(€) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 11/06/2025 | €1.22 B | $1.41 B | -12.22% | 8292 |
| 12/31/2024 | €1.39 B | $1.44 B | 88.09% | 7042 |
| 12/29/2023 | €738.49 M | $815.1 M | -36.23% | 9852 |
| 12/30/2022 | €1.16 B | $1.24 B | 12.13% | 7256 |
| 12/30/2021 | €1.03 B | $1.17 B | -21.36% | 8498 |
| 12/31/2020 | €1.31 B | $1.6 B | 66.28% | 6082 |
| 12/31/2019 | €789.8 M | $885.6 M | 227.46% | 7348 |
| 12/31/2018 | €241.19 M | $276.55 M | -56.08% | 12252 |
| 12/29/2017 | €549.17 M | $658.67 M | -8.43% | 9075 |
| 12/30/2016 | €599.75 M | $630.69 M | -47.54% | 8566 |
Company Profile
About Pharma Mar, S.A.
Pharma Mar, S.A. is a biopharmaceutical company specializing in oncology treatments. The company operates globally, with a focus on research, development, production, and commercialization of bio-active principles for cancer therapy.
Business Segments
- Oncology: Develops and markets treatments for various cancers.
- RNA Interference: Focuses on gene expression reduction and silencing for therapeutic applications.
Key Products & Pipeline
- Yondelis: Used for soft tissue sarcoma and ovarian cancer.
- Aplidin: Treats relapsed/refractory multiple myeloma.
- Zepzelca: Targets small cell lung cancer.
- Ecubectedin (PM14): In Phase II trials for solid tumors and Phase I for soft tissue sarcoma & prostate cancer.
- PM534 & PM54: Phase I trials for solid tumors.
- SYL1801: Phase II trials for macular degeneration.
- SYL116011: Preclinical studies for ocular allergies.
- SYL A & B: Investigational studies for retinitis pigmentosa.
Operations & History
Pharma Mar, S.A. serves markets in Spain, Italy, Germany, Ireland, France, the EU, the United States, and internationally. Founded in 1986, the company is headquartered in Madrid, Spain.
Frequently Asked Questions
-
What is Pharma Mar, S.A.'s (BME-PHM) current market cap?As of 11/06/2025, Pharma Mar, S.A. (including the parent company, if applicable) has an estimated market capitalization of $1.41 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Pharma Mar, S.A. (BME-PHM) rank globally by market cap?Pharma Mar, S.A. global market capitalization ranking is approximately 8292 as of 11/06/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.